NCT02231190 - GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2015

Primary Completion Date

June 12, 2015

Study Completion Date

June 12, 2015

Conditions

Tendon Injuries

Interventions

DRUG

GSK1278863

GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise

DRUG

Placebo

GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise

Trial Locations (1)

21225

GSK Investigational Site, Baltimore